X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GSK PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GSK PHARMA CADILA HEALTHCARE/
GSK PHARMA
 
P/E (TTM) x 23.9 67.7 35.3% View Chart
P/BV x 6.0 11.9 50.6% View Chart
Dividend Yield % 0.8 1.1 73.5%  

Financials

 CADILA HEALTHCARE   GSK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
GSK PHARMA
Mar-17
CADILA HEALTHCARE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4603,838 12.0%   
Low Rs3052,637 11.6%   
Sales per share (Unadj.) Rs92.1354.2 26.0%  
Earnings per share (Unadj.) Rs14.839.8 37.3%  
Cash flow per share (Unadj.) Rs18.542.9 43.1%  
Dividends per share (Unadj.) Rs3.2030.00 10.7%  
Dividend yield (eoy) %0.80.9 90.3%  
Book value per share (Unadj.) Rs68.0236.9 28.7%  
Shares outstanding (eoy) m1,023.7484.70 1,208.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.29.1 45.4%   
Avg P/E ratio x25.881.4 31.7%  
P/CF ratio (eoy) x20.775.5 27.4%  
Price / Book Value ratio x5.613.7 41.2%  
Dividend payout %21.675.4 28.6%   
Avg Mkt Cap Rs m391,581274,216 142.8%   
No. of employees `00016.94.7 358.8%   
Total wages/salary Rs m15,0024,830 310.6%   
Avg. sales/employee Rs Th5,594.56,387.0 87.6%   
Avg. wages/employee Rs Th890.11,028.3 86.6%   
Avg. net profit/employee Rs Th899.9717.1 125.5%   
INCOME DATA
Net Sales Rs m94,29530,000 314.3%  
Other income Rs m1,286728 176.6%   
Total revenues Rs m95,58130,728 311.1%   
Gross profit Rs m19,0364,190 454.3%  
Depreciation Rs m3,750263 1,425.9%   
Interest Rs m4500-   
Profit before tax Rs m16,1224,655 346.3%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3457 -0.7%   
Tax Rs m1,2891,744 73.9%   
Profit after tax Rs m15,1683,368 450.4%  
Gross profit margin %20.214.0 144.5%  
Effective tax rate %8.037.5 21.3%   
Net profit margin %16.111.2 143.3%  
BALANCE SHEET DATA
Current assets Rs m60,22316,742 359.7%   
Current liabilities Rs m53,0587,202 736.7%   
Net working cap to sales %7.631.8 23.9%  
Current ratio x1.12.3 48.8%  
Inventory Days Days7052 134.8%  
Debtors Days Days8821 424.2%  
Net fixed assets Rs m72,9848,635 845.2%   
Share capital Rs m1,024847 120.9%   
"Free" reserves Rs m68,57619,222 356.8%   
Net worth Rs m69,60020,069 346.8%   
Long term debt Rs m24,68410 246,840.0%   
Total assets Rs m152,20730,038 506.7%  
Interest coverage x36.8NM-  
Debt to equity ratio x0.40 71,174.2%  
Sales to assets ratio x0.61.0 62.0%   
Return on assets %10.311.2 91.5%  
Return on equity %21.816.8 129.9%  
Return on capital %17.925.5 70.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,280528 4,030.3%   
Fx outflow Rs m10,8747,193 151.2%   
Net fx Rs m10,406-6,665 -156.1%   
CASH FLOW
From Operations Rs m13,4952,360 571.8%  
From Investments Rs m-29,1033,008 -967.5%  
From Financial Activity Rs m23,158-5,108 -453.4%  
Net Cashflow Rs m7,556260 2,902.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.3 10.2 81.4%  
FIIs % 5.9 23.8 24.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 102,036 43.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 22, 2018 03:37 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - STRIDES SHASUN LTD COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS